Damora Therapeutics (DMRA) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Damora Therapeutics (DMRA) over the past year, gaining 130.1% versus a gain of 93.1%. Damora Therapeutics is the larger company by market cap ($1.27 billion vs $1.12 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | LBRX |
|---|---|---|
| Share price | $20.56 | $34.61 |
| Market cap | $1.27B | $1.12B |
| 1-day change | +1.58% | +1.32% |
| YTD return | -10.65% | +55.48% |
| 1-year return | +93.05% | +130.12% |
| 5-year return | -75.95% | — |
| P/E ratio (TTM) | — | 346.10 |
| EPS (TTM) | $-0.25 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $50.16 |
| 52-week low | $4.95 | $14.32 |
| Distance from 52-week high | -46.35% | -31.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.06% | +65.56% |
| Average volume | 531.94K | 341.17K |
| Shares outstanding | 61.74M | 32.26M |
| Employees | 7 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed DMRA by 37.1 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
DMRA vs LBRX FAQ
Which is bigger, Damora Therapeutics or LB Pharmaceuticals?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.27B compared with $1.12B for LB Pharmaceuticals (LBRX).
Which stock has performed better over the past year, DMRA or LBRX?
LBRX returned +130.12% over the past 12 months, compared with +93.05% for DMRA (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and LB Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.